I am mostly out of AMRN because of a delayed binary event. AMRN applied for a label change to the FDA that would increase available market by a huge amount. Problem is that if the FDA does not grant label change priority review, AMRN stock could temporarily tank. If it does, the stock could sky rocket. Canada granted priority review, but US FDA is now political. I sort of hoped my last few hundred shares would have been called away Friday, but price missed by 0.25. Advantage of using your rolling strategy for biotechs is that selling put or calls generates 3% of share price per week each. I see politics as a problem with indices too so I am not sure what to do.
